The transforming growth factor-β (TGFβ) superfamily of cytokines, which consists of TGFβs, activins, inhibins, Nodal, bone morphogenetic proteins (BMPs), antiMüllerian hormone (AMH; also known as Müllerian-inhibiting factor) as well as growth and differentiation factors (GDFs), is conserved through evolution and found in all multicellular organisms 1 . The TGFβs per se are involved in many cellular processes, including growth inhibition, cell migration, invasion, epithelial-mesenchymal transition (EMT), extracellular matrix (ECM) remodelling and immune-suppression 2 . However, although normally dynamically regulated and involved in maintenance of tissue homeostasis, TGFβs are often chronically overexpressed in disease states, including cancer, fibrosis and inflammation, and this excessive production of TGFβ drives disease progression by modulating cell growth, migration or phenotype. The TGFβ signalling pathway has therefore become a popular target for drug development.
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. The TGFβs per se are involved in many cellular processes, including growth inhibition, cell migration, invasion, epithelial-mesenchymal transition (EMT), extracellular matrix (ECM) remodelling and immune-suppression 2 . However, although normally dynamically regulated and involved in maintenance of tissue homeostasis, TGFβs are often chronically overexpressed in disease states, including cancer, fibrosis and inflammation, and this excessive production of TGFβ drives disease progression by modulating cell growth, migration or phenotype. The TGFβ signalling pathway has therefore become a popular target for drug development.
Knowledge about cellular activities gleaned from studying one disease is often applicable to others. For example, inhibition of TGFβ-induced EMT -a process that contributes to cancer progression -is a goal not only of oncologists but also of cardiovascular surgeons to prevent neointimal hyperplasia, and of nephrologists and pneumologists in the treatment of fibrosis 3 . In addition, the immune-modulatory activities of TGFβ have implications in many diseases, including cancer, cardiovascular disease, asthma, rheumatoid arthritis and multiple sclerosis 4 . TGFβ action is highly context-dependent and influenced by cell type, culture conditions, interaction with other signalling pathways, developmental or disease stage in vivo and innate genetic variation among individuals [5] [6] [7] [8] [9] . This makes the pathway a particular challenge for drug development. Nevertheless, over the past decade several drugs targeting the TGFβ signalling pathway have been developed by pharmaceutical companies and biotechnology firms alike. Drug design strategies have been numerous and include the development of small-molecule inhibitors (SMIs) and monoclonal antibodies, as well as the inhibition of gene expression; some drugs have reached Phase III clinical trials for a number of disease applications, particularly fibrosis and oncology. There is an increasing number of preclinical examples of TGFβ inhibitors that are capable of reducing cancer progression and metastasis, and that augment existing cancer therapies (such as radiation therapy in breast cancer) while simultaneously guarding against radiation-induced fibrosis 10 . Additionally, there are novel reports of targeting TGFβ signalling in less prevalent indications, such as reduction of vascular symptoms of Marfan syndrome (MFS) 11, 12 . Although there have been many reviews on the pleiotropic action of TGFβ during tumorigenesis, which is characterized by tumour-suppressing activity of TGFβ at an early stage of cancer and tumour-promoting activity at later stages [13] [14] [15] [16] , few focus specifically on drug targets, drug classes and possible therapeutic applications beyond the oncology arena. The translation of anti-TGFβ therapies has been pursued most intensively for oncology; however, this Review also discusses the potential of the TGFβ signalling pathway as a target for non-neoplastic disease therapies and addresses the associated challenges in the development and application of these strategies.
Fibrosis
The excess accumulation of fibroblasts and associated extracellular matrix.
Metastasis
The dissemination of tumour cells and re-establishment of tumours at a secondary site.
SMAD
Signal transduction component of the canonical transforming growth factor-β signalling pathway. The TGFβ family The vertebrate genome contains more than 30 pleiotropic ligands that belong to the TGFβ superfamily, including TGFβs, BMPs, GDFs, activins, inhibins, Nodal and AMH 1 . TGFβ has a conserved motif of nine cysteine residues, eight of which form a tight cysteine knot, with the ninth being crucial for homodimerization 2 . Aberrant expression and activity of many of the ligands of the TGFβ superfamily are associated with developmental defects and human diseases 17 . Here we focus on TGFβs as there are currently several clinical trials underway involving therapies targeting TGFβ signalling, whereas other members of the TGFβ superfamily are under-represented in current trials.
Three highly homologous isoforms of TGFβ exist in humans: TGFβ1, TGFβ2 and TGFβ3. They share a receptor complex and signal in similar ways but their expression levels vary depending on the tissue 18 , and their functions are distinct as demonstrated by the phenotypes of knockout mice [19] [20] [21] [22] [23] . Each TGFβ ligand is synthesized as a precursor, which forms a homodimer that interacts with its latency-associated peptide (LAP) and a latent TGFβ-binding protein (LTBP), forming a larger complex called the large latent complex (LLC). The TGFβ activation process involves the release of the LLC from the ECM, followed by further proteolysis of LAP to release active TGFβ to its receptors 2 . Matrix metalloproteinase 2 (MMP2) and MMP9 are known to cleave latent TGFβ. In addition to MMPs, thrombospondin 1 (THBS1) is known to activate latent TGFβ 24 . Alternatively, upon mechanical stretch, αVβ6 integrin can activate TGFβ by binding to the RGD motif present in LAP and inducing the release of mature TGFβ from its latent complex 25, 26 .
TGFβ signalling
Proteolytic cleavage, interaction with integrins or pH changes in the local environment are known to activate latent TGFβ and free active TGFβ for binding to its receptors at the cell membrane. TGFβ superfamily members signal via heteromeric complexes of two related transmembrane type I and type II serine/threonine kinase receptors. Five type II receptors and seven type I receptors (also termed activin receptor-like kinases (ALKs)) have been identified. Auxilliary co-receptors (also known as type III receptors) that regulate the access of TGFβ superfamily members to signalling receptors also exist. Each subfamily of the TGFβ superfamily of ligands binds to type I and type II receptors
. BMPs can bind to type I receptors alone and, in their absence, can weakly bind to type II receptors, but they show highest affinity when both receptors act together. TGFβ and activin display high affinity only for type II receptors and do not normally interact with isolated type I receptors. Binding to the extracellular domains of type I and type II receptors by the dimeric ligand induces close proximity and a productive conformation for the intracellular serine/threonine kinase domains of the receptors, facilitating the phosphorylation and subsequent activation of the type I receptor. The activation of the type I receptor leads to the propagation of signalling by at least two seemingly independent routes: the SMAD-dependent canonical pathway (BOX 1; FIG. 1) and the SMAD-independent or non-canonical pathways In the SMAD-dependent pathway, activation of TGFβ receptor type I (TβRI; also known as TGFBR1 and ALK5) leads to phosphorylation of receptor-specific SMAD (R-SMAD) proteins. SMAD2 and SMAD3 are substrates of TβRI, whereas type I receptors for BMPs utilize SMAD1, SMAD5 and SMAD8 (FIG. 1) . Upon phosphorylation by the receptor, R-SMADs together with the common mediator SMAD4 (co-SMAD) translocate to the nucleus, where they interact with other transcription factors (cofactors) to regulate transcriptional responses 27 (FIG. 1) . In addition to the canonical role of SMADs as transcription factors, a novel role for R-SMADs in the post-transcriptional regulation of microRNA (miRNA) biogenesis has been identified 28 (FIG. 1) . Therefore, the canonical TGFβ-SMAD pathway modulates gene expression both transcriptionally and post-transcriptionally to propagate the physiological and pathological activities of TGFβ. In the non-canonical pathway, the activated TGFβ receptor complex transmits a signal through other factors, such as tumour necrosis factor (TNF) receptor-associated factor 4 (TRAF4), TRAF6, TGFβ-activated kinase 1 (TAK1; also known as MAP3K7), p38 mitogen-activated protein kinase (p38 MAPK), RHO, phosphoinositide 3-kinase (PI3K), AKT (also known as protein kinase B), extracellular signal-regulated kinase (ERK), JUN N-terminal kinase (JNK) or nuclear factor-κB (NF-κB) FIG. 2) . Thus, cellular responses to TGFβ signalling result from the dynamic combination of canonical and non-canonical signalling cascades. In addition to the complexity generated by the canonical and non-canonical TGFβ signalling pathway, TGFβ signalling can be influenced by different signalling pathways, including the PI3K-AKT, WNT, Hedgehog (HH), Notch, interferon (IFN), TNF and RAS pathways (BOX 2; FIG. 2) . Interactions with several of these pathways can change the output of TGFβ signalling from suppressing growth to inducing cellular plasticity 29 . Nuclear accumulation and transcriptional activity of R-SMADs can also be negatively regulated through phosphorylation of multiple Ser-Pro and Thr-Pro residues (in the linker region connecting the MH1 and MH2 domains) by ERK, MAPKs, calcium/calmodulindependent protein kinase II and cyclin-dependent kinases (CDKs) 30 . The mode and outcome of the crosstalk between TGFβ and other signalling pathways vary considerably but are essential to define the activities of TGFβ in propagating spatially and temporally specific outputs 6, 31, 32 .
Biological actions of TGFβ
TGFβ is involved in a range of biological processes both during embryogenesis and in adult tissue homeostasis. Although the physiological roles of TGFβ have been extensively reviewed elsewhere 16, [33] [34] [35] [36] , the major functions of TGFβ that are relevant to the topic of this Review are briefly outlined below.
Inhibition of cell proliferation. TGFβ strongly inhibits the growth of many cell types, including epithelial, endothelial, haematopoietic and immune cells 37, 38 . TGFβ also has pro-apoptotic and differentiation-inducing actions on epithelial cells; together, these actions result in tumour suppression in the context of cancer 34 . TGFβ in epithelial cells activates transcription of cyclin-dependent kinase inhibitor 1A (CDKN1A) and CDKN2A (which encode p21 CIP1 and p15 INK4B , respectively) to mediate cell cycle arrest at the G1 phase 39 . Conversely, TGFβ represses the transcription of MYC, which encodes a potent transcriptional activator of genes that is required for cell proliferation and growth, and inhibitor of DNA binding (ID) family genes, which encode transcription factors that promote cell differentiation and determination 40 . In oncology, many tumours attenuate TGFβ growth-inhibitory effects but respond to this ligand in a pro-tumorigenic manner. Thus, depending on the tumour type and the stage of tumour progression, TGFβ may provide potent tumoursuppressive or tumour-promoting functions directly on the tumour cell, presumably by mediating differential gene expression programmes (FIG. 3) .
Unlike the role of TGFβ signalling during tumorigenesis, the contribution of TGFβ to vascular disease is more complex and confusing. Studies on clinical samples from vascular disorders, such as atherosclerosis, hypertension and pulmonary hypertension, often find signatures of both upregulation and downregulation of TGFβ signalling, as well as complex interactions between this pathway and other ligands of the TGFβ family, such as BMPs
. This has been confirmed by in vitro studies, demonstrating the contradictory effects of TGFβ in the regulation of vascular cells 36, 41 . Furthermore, the TGFβ pathway often exhibits contrasting effects in different vascular cell types, such as endothelial versus vascular smooth muscle cells 36 . The promiscuous and cell typespecific action of the TGFβ pathway on vascular cells makes the application of targeted TGFβ signalling therapies for cardiovascular disease a particular challenge.
Induction of epithelial-mesenchymal transition and the myofibroblast phenotype. TGFβ can induce an EMT of both epithelial and endothelial cells. This has consequences for disease progression in both cancer and fibrosis 3 . EMT enhances cellular migration and invasive properties, as cell migration requires loss of cell-cell contacts and acquisition of fibroblastic characteristics.
Box 1 | Canonical signal transduction pathway of the TGFβ superfamily of growth factors
The basic framework of the canonical signal transduction pathways of three subfamilies of the transforming growth factor-β (TGFβ) superfamily -TGFβs, activins/inhibins/Nodal and bone morphogenetic proteins (BMPs) -is highly conserved. The ligand binds to a specific set of type I and type II receptors, which are both serine/threonine kinases, followed by signal transduction by SMAD proteins 31, 205 . Although each subfamily transmits the signal through a specific signalling pathway, the interaction among the TGFβ, activins/inhibins/Nodal and BMP subfamilies is well recognized during development and in postnatal homeostasis of various organs
. Upon ligand binding and resultant heterotetrameric receptor complex formation, the constitutively active type II receptor phosphorylates the type I receptor, which in turn propagates a signal by phosphorylating the receptor-specific SMADs (R-SMADs) 31, 205 . Unlike type I and type II receptors, type III receptors do not possess kinase activity and are not required for signal transduction; however, they bind to specific ligands and modulate the signalling pathway either positively or negatively 31, 205 . Phosphorylation of R-SMADs at two serine residues within the extreme carboxyl terminus by type I receptor kinase activity promotes association with the common mediator SMAD (co-SMAD), SMAD4, resulting in nuclear accumulation and sequence-specific binding to DNA in concert with other DNA-binding transcription factors that bind distinct sequences adjacent to the SMAD-binding element (SBE) 27 , and together these complexes modulate transcription. The inhibitory SMADs (I-SMADs), SMAD6 and SMAD7, antagonize R-SMAD activation by competing with R-SMADs for type I receptor interaction and/or by recruiting specific ubiquitin ligases or phosphatases to the activated receptor complex, thereby targeting it for proteasomal degradation or dephosphorylation, respectively. SMAD7 inhibits signalling from all branches of the TGFβ superfamily, whereas SMAD6 is a specific inhibitor of the BMP signalling pathway. The table indicates the basic molecules in the signal transduction pathway, including three types of receptors and SMADs, for three subfamilies of the TGFβ superfamily of ligands: TGFβs, activins/ inhibins/Nodal and BMPs. E-cadherin is commonly downregulated in many cancers, and its overexpression can suppress invasion by tumour cells. The TGFβ-SMAD pathway mediates the expression of high mobility group AT-hook 2 (HMGA2), which is important for the induction of SNAIL (also known as SNAI1) and SLUG (also known as SNAI2): two zinc-finger transcription factors that are known to repress the E-cadherin gene 33 . In breast and skin cancer, tumour cell EMT contributes to cancer progression as cells consequently become more migratory and invasive, and they can ultimately transition to a myofibroblastic phenotype 3 . The myofibroblast further modulates the basic biology of the tumour by increasing ECM elaboration and eliciting a tissue contraction process, which results in increased interstitial fluid pressure (IFP). This has consequences for the efficiency of drug delivery to the tumour 42 , as drugs cannot penetrate tissue under positive IFP. EMT can also polarize carcinoma cells towards 'stem cell-like' properties, such as increased tumour-initiating capacity and tumour cell drug resistance 43 . Blocking the TGFβ pathway can thus have a threefold benefit: the reduction of tumour invasion and metastasis; the suppression of cancer stem cell-like properties; and the restoration of negative IFP to enhance chemotherapeutic drug delivery 44 . In fibrotic conditions, excessive TGFβ production induced in the diseased state contributes to EMT elaboration, which can further exacerbate fibrosis, as seen in pulmonary 45, 46 , cardiac 47 and renal 48, 49 fibrosis, and in arterial restenosis following surgical trauma 50 . TGFβ can also promote a proliferative and/or migratory phenotype on smooth muscle cells that can aggravate some vascular diseases, including neointimal formation following vascular surgery [51] [52] [53] . Extracellular matrix regulation. The ECM is a complex structure that surrounds mammalian cells. It is the major component of connective tissue and is composed of multiple proteins, such as collagen, elastin, fibrillin, fibronectin, lamin and proteoglycans. Fibrosis is characterized by the accumulation of fibroblasts, which secrete excessive amounts of ECM. As TGFβ is widely documented to increase collagen synthesis and deposition by fibroblasts, TGFβ has become a central therapeutic target for different types of fibrosis. TGFβ activity and the synthesis of ECM proteins are mutually regulated. Several genes encoding ECM proteins that are known to be important in driving fibrosis are directly regulated by TGFβ-SMAD signalling pathways. There is a reciprocal regulation of TGFβ by the ECM: latent TGFβ bound to ECM components, such as fibronectin and fibrillin, is inactive until physiological or pathological processes initiate its release. This is seen in MFS, in which the mutation of a fibrillin-encoding gene results in reduced fibrillin levels and a consequent increase in levels of unbound TGFβ; this, in turn, leads to the activation of TGFβ signalling, which is possibly responsible for the aetiology of many Marfanoid features 11, 12 .
Molecular category
Immune-suppression and inflammation. The lethal postnatal inflammatory phenotype of Tgfb1-knockout mice 19, 20, 54 demonstrates the important immune-suppressor function of this ligand. The widespread expression profile of TGFβ receptors on all immune cell types suggests that they have broad activities, including responses in cytotoxic CD8 + effector T cells, CD4 + effector T helper 1 (T H 1) and T H 2 cells, suppressive regulatory T (T Reg ) cells, natural killer (NK) cells, monocytes, macrophages, neutrophils and eosinophils (FIG. 4) . Cell type-specific mouse gene knockout studies with Tgfbr2 demonstrate both direct and indirect actions of TGFβ on effector T cells 4 . Upon activation, TGFβ dimers induce heteromeric complex formation between specific type II and type I receptors (such as TGFβ receptor type II (TβRII) and TβRI, respectively). Type II receptors then transphosphorylate the type I receptors, which propagate the signal into the cell by phosphorylating TGFβ receptor-specific SMADs (R-SMADs: SMAD2 and SMAD3). They form heteromeric complexes with the common mediator SMAD (co-SMAD: SMAD4) and translocate to the nucleus. Once in the nucleus, the R-SMAD-co-SMAD complex preferentially associates with the genomic SMAD-binding element (SBE) in a sequence-specific manner. However, high-affinity binding of the R-SMAD-co-SMAD complex with the SBE generally occurs in concert with other DNA-binding transcription factors that bind to distinct sequences adjacent to the SBE 27 . The nuclear proteins SKI and SNO (also known as SKIL) antagonize the transcriptional regulation by SMADs. An inhibitory SMAD (I-SMAD), SMAD7, inhibits the TGFβ pathway through multiple mechanisms, including by mediating the degradation of the type I receptor, inhibiting phosphorylation of R-SMADs by the type I receptor kinase or inhibiting the formation of the R-SMAD-co-SMAD complex. In addition to regulating transcription, R-SMADs can modulate microRNA (miRNA) biogenesis by facilitating the processing of primary miRNA into precursor miRNA in the nucleus. The co-SMAD is not required for the regulation of miRNA biosynthesis by R-SMADs. 'mG' and 'AAAAA' represent 5ʹ capping and 3ʹ polyadenylation of mRNAs, respectively.
Antisense oligonucleotides (ASOs). Short chemically modified oligonucleotides complementary to a specific mRNA that can be used to cause specific knockdown of targeted gene expression.
TGFβ has potent growth-suppressing activity on most precursor cells of the immune system, particularly T and B cells of the adaptive arm. TGFβ is a potent suppressor of T cell proliferation 55 + T cell-specific ablation of TGFβ signalling in transgenic mice expressing dominant negative TβRII (DNRII; also known as CD4-ΔTβRII and CD4-ΔTGFBR2) led to the development of autoimmunity 58 and enhanced the differentiation of CD8 + cytotoxic T lymphocytes (CTLs). When challenged with tumour cells, these transgenic mice raised a greater tumour-specific CTL response than wild-type littermates 58 . Tumour-derived TGFβ also blocks the differentiation of antigen-presenting dendritic cells 59 and modifies chemokine receptor expression to blunt dendritic cell chemotaxis 60 , further suppressing immune surveillance.
In addition to having a predominant immune-suppressive function, TGFβ counterintuitively may have a pro-inflammatory role through its effects on T H 17 cells and cells of the innate immune system. TGFβ, together with interleukin-6 (IL-6), was reported to be an essential player in driving pro-inflammatory T H 17 lineage differentiation [61] [62] [63] . However, there is considerable controversy surrounding this topic. First, different laboratories cannot agree on the specific functions of various T H 1, T H 2 and T H 17 cell types in disease progression. T H 17 cells were implicated as major agonists in inflammatory diseases, including inflammatory cancer, asthma and autoimmune disorders 55 . However, recent studies suggest that the active player in disease progression is in fact a T H 17-derived T H 1 cell, or a 'T H 1-T H 17' cell 64 . Second, the role of TGFβ in regulating the balance between T H 1 and T H 17 differentiation is in dispute. Despite the widespread acceptance of a role for TGFβ in T H 17 differentiation [61] [62] [63] , more recent studies have suggested that TGFβ is totally dispensable for the generation of these cells 65, 66 .
With respect to cells of the innate immune system, TGFβ directly suppresses NK cell-mediated production of IFNγ (which is required for the tumour killing activity of NK cells) through transcriptional effects of SMAD3 on the IFNγ promoter 67 . It also 'polarizes' macrophages 68 and neutrophils 69 from a type I, productive phenotype (that evolved to attack and devour foreign agents such as cancer cells) towards a type II phenotype (that has reduced effector function but produces large quantities of inflammatory molecules, such as IL-6, IL-11 and TGFβ). These molecules can exacerbate the local diseased state, resulting in solid tumour progression or inflammation associated with fibrosis or atherosclerosis 4 . In summary, the regulation of the immune system by TGFβ is highly complex and context-dependent. It delicately regulates the tolerogenic versus immunogenic arms of the immune system to balance adequate host defence while limiting collateral inflammatory tissue damage. The molecular details of this regulation have been recently reviewed in depth 4, 55, 64 .
Targeting TGFβ signalling
Virtually every component of the TGFβ pathway has been targeted for drug development (FIG. 5) through numerous design strategies (FIG. 6) . Several have been developed through preclinical to clinical trials (TABLE 1) and many more have been tested only in preclinical systems (TABLE 2 . The various approaches currently being investigated are discussed in more detail below.
Antisense oligonucleotides and antisense RNA. Antisense Pharma uses the strategy of targeting mRNA translation using ASOs to downregulate ligand synthesis 70, 83 . Its focus has been on targeting TGFβ2, which is produced in excessive quantities by glioblastoma and pancreatic carcinoma cells. Trabedersen (AP12009), a synthetic 18-mer phosphorothioate ASO, binds specifically to human TGFΒ2 mRNA, and this drug has progressed to a Phase III clinical trial for oncology applications (BOX 4) . One of the challenges of this drug is delivering it directly to the tumour
Box 2 | Non-canonical TGFβ signalling and crosstalk with other pathways
In addition to activating SMAD proteins, transforming growth factor-β (TGFβ) signalling can regulate the activity of a number of signalling molecules, such as TNF receptor-associated factor 4 (TRAF4), TRAF6, TGFβ-activated kinase 1 (TAK1), p38 mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK), JUN N-terminal kinase (JNK), RHO GTPases, phosphoinositide 3-kinase (PI3K)-AKT and nuclear factor-κB (NF-κB), to transmit a signal 6 . In addition, these non-canonical signals can crosstalk with the SMAD pathways and mutually modulate each other. Both canonical and non-canonical TGFβ signalling can also be influenced by other signalling pathways, such as the RAS, WNT, Hedgehog, Notch, tumour necrosis factor (TNF) and interferon pathways 6 . The exact nature of the crosstalk with other pathways and biological outcomes is complex and highly context-dependent 6 . However, some of the crosstalk has been found to modulate the function and stability of SMAD proteins through post-translational modifications, and to define cell typeand context-specific outcomes by inducing other factors that modulate TGFβ activity. to avoid the off-target toxicity associated with systemic delivery of first-generation ASOs. In the case of glioblastoma, this was achieved using intrathecal catheter delivery directly into the tumour 74 . More recently, the company has started developing intravenous delivery approaches for pancreatic cancer, which appear to be effective in mouse models 73 and were recently shown to be safe in humans 84 . An anti-TGFB2 antisense strategy has also been used to generate augmented tumour vaccines. Belagenpumatucel-L (Lucanix; NovaRx) is such a drug, in which an ~900-nucleotide TGFB2 antisense construct is transfected into allogeneic non-small-cell lung cancer (NSCLC) cells, which are then used as a tumour vaccine. Here, drug delivery is not an issue as the 'drug' is in fact genetically engineered NSCLC tumour cell lines. This tumour vaccine has superior activity compared to conventional tumour vaccination approaches 85, 86 . A significant dose-related survival difference was seen in patients who received 2.5 × 10 7 cells per injection, allowing progression to a Phase III clinical trial 87 .
Monoclonal antibodies. The advantages of monoclonal antibodies are their specificity and extracellular mechanism of action -an advantage when trying to mop up excess extracellular ligand. This is tempered by the less con venient intravenous mode of delivery. However, prolonged pharmacokinetic stability permits infrequent drug administration. Cambridge Antibody Technologies and Genzyme developed humanized (or murinized for preclinical studies) monoclonal antibodies specific to individual ligands, such as lerdelimumab 88,89 and metelimumab 
90
, or with pan-ligand specificity, such as fresolimumab (GC-1008) [91] [92] [93] . These antibodies have proceeded through various stages of preclinical and clinical development. Of these three humanized antibodies, fresolimumab has progressed furthest in the clinic for both neoplastic and non-neoplastic applications. This drug was found to be well tolerated and safe at 15 mg per ml in Phase I trials for metastatic melanoma (MetM) plus renal cell carcinoma 93 . Despite a promising Phase I oncology trial of fresolimumab, after Genzyme was acquired by Sanofi the company made the decision to focus on fibrotic applications of this drug.
Eli Lilly entered the monoclonal antibody arena with a TGFβ1 ligand-selective blocking antibody, LY2382770, which has progressed to Phase II trials for kidney fibrosis (TABLE 1) . Since merging with ImClone, Eli Lilly has also developed a TβRII-blocking antibody, IMC-TR1 (REF. 94 ), which has just entered clinical trials for breast and colon cancer (ClinicalTrials.gov identifier: NCT01646203). In addition, Biogen Idec and Stromedix have developed an anti-integrin β6 antibody that prevents the activation of TGFβ and has been used efficaciously in preclinical studies of fibrosis and cancer 95 ; it is in a Phase II trial for fibrosis (ClinicalTrials.gov identifier: NCT01371305).
Ligand traps and peptides. Genzyme developed a ligand trap by fusing Fcγ to the extracellular domain of TβRII, but this construct never reached clinical trials 96 . However, an alternative ligand trap approach, pursued by Digna Biotech, using peptide mimetics of TβRIII (also known as betaglycan and TGFBR3), completed a Phase IIa clinical trial for scleroderma and skin fibrosis, showing safety and efficacy when topically applied to skin (TABLE 1; BOX 4) . This company has plans to extend to Phase IIb/III trials in 2013 (J. Dotor, personal communication). A peptide antagonist of TGFβ activation, LSKL (Leu-Ser-Lys-Leu), binds to a conserved sequence in the LAP region of the latent complex and has demonstrated efficacy in reducing TGFβ signalling in vitro 97 . This antagonist is based on thrombospondin and specifically blocks TGFβ activation. The issue of peptide drug delivery is not a problem for topical application; however, to progress to systemic delivery, Digna Biotech has partnered with Flamel Technologies to investigate proprietary peptide delivery systems.
Small-molecule inhibitors. There are a plethora of SMIs that specifically target the type I receptor of TGFβ to inhibit the phosphorylation of SMAD2 and SMAD3 while keeping at least some non-canonical responses, such as TAK1 activation, intact. These drugs are generally ATP mimetics that bind competitively within the hydrophobic ATP binding pocket of the receptor kinase. Transforming growth factor-β (TGFβ) has biphasic actions during tumorigenesis, suppressing tumorigenesis at early stages but promoting tumour progression later on, which is the underlying paradigm for the action of TGFβ during disease progression in general and thus complicates the development of therapies targeting TGFβ signalling. The light grey arrows indicate a positive feedforward loop resulting in higher levels of TGFβ, which is a feature of non-neoplastic as well as neoplastic diseases. The current goal in cancer therapy is to downmodulate excessive levels of TGFβ ligands and to target the tumour-progressing versus the tumour-suppressing arm of TGFβ action; the latter goal will almost certainly require more-specific second-generation drugs. CTGF, connective tissue growth factor; EMT, epithelial-mesenchymal transition; IL, interleukin; PTHRP, parathyroid hormone-related protein; TAMs, tumour-associated macrophages; TANs, tumour-associated neutrophils; VEGF, vascular endothelial growth factor.
The chemistry of these compounds has been extensively reviewed 98,99 and some molecular structures are shown in FIG. 6 . The obvious advantages of these molecules over most others are their economical production, stability and ease of oral administration, set against a possible disadvantage of cross-inhibition of other kinases. The short half-life of these drugs provides the possibility of rapid drug withdrawal should adverse events arise. Many successful preclinical studies for metastatic cancer have been undertaken with these SMIs, as reviewed previously 100, 101 . However, the only company to continue pursuit of a TβRI-targeted SMI into clinical trials for oncology is Eli Lilly with LY2157299 (REF. 82) (ClinicalTrials.gov identifier: NCT01373164).
Other approaches. A novel approach to the suppression of ligand production has been the preclinical development of pyrrole-imidazole polyamides that bind with sequence specificity to the TGFB1 gene promoter to attenuate gene expression 50, 102, 103 . These large ~17 kDa polymeric molecules (FIGS 5, 6) bind within the minor groove of DNA to prevent transcription factor binding. Challenges associated with these drugs include the specificity of promoter binding, along with drug delivery issues owing to their large molecular size and the high local concentration required for activity. However, preclinical studies suggest that these molecules might be used in drug-eluting stents for the purpose of reducing restenosis after coronary or carotid artery surgery 50 . An alternative approach to suppress TGFβ signalling is gene transfer of antagonizing signalling molecules, such as the inhibitory SMAD7. This approach has been applied in model systems to treat or prevent various pathological conditions, including colonic and hepatic fibrosis, vascular remodelling and diabetic kidney disease 104, 105 . Such an application has the potential to be applied to many other systemic diseases to attenuate the activity of the TGFβ pathway, with the caveat that gene therapy is still far from being widely accepted as a therapeutic approach 106 . As an approach to stimulate immune destruction of cancer cells by tumour-infiltrating T cells, human tumour antigen-specific CTLs have been engineered to express DNRII using [108] [109] [110] [111] . This approach is in a Phase I clinical trial for advanced HER2-positive lung malignancy, labelled the HERCREEM trial (ClinicalTrials. gov identifier: NCT00889954).
Finally, Renova has developed a recombinant TGFβ3 ligand as an anti-scarring agent on the basis of the hypothesis that this ligand has activity that is independent of and antagonistic to TGFβ1 (REF. 112 ). The drug, administered by injection around a surgical wound site, progressed to a Phase III clinical trial, but unfortunately it did not reach its primary or secondary efficacy end points.
Pre-existing drugs that inhibit TGFβ. Pre-existing drugs that have been extensively used for other applications may act, in part, by inhibiting TGFβ. Examples are losartan and candesartan, which are angiotensin type II receptor inhibitors that were originally developed for the treatment of hypertension. Both appear to reduce TGFβ signalling, although the precise molecular mechanisms of this action are still unclear 12, [113] [114] [115] . Pirfenidone acts in part by reducing the fibrotic effects of TGFβ 116 via unknown targets. It is the first approved drug in Europe for idiopathic pulmonary fibrosis (IPF), and is in a Phase III trial in the United States 117, 118 . On the other side of the coin, some common drugs, including aspirin, elevate circulating TGFβ levels, which -in certain cases such as arteriosclerosis -correlates with disease suppression 119 .
Therapeutic uses of TGFβ signalling inhibition
Cancer. TGFβ has a biphasic action during tumorigenesis, suppressing tumorigenesis at early stages but promoting tumour progression later on (FIG. 3) . This is a paradigm for the action of TGFβ during disease progression in general, including that of fibrosis, inflammation and cardiovascular disease, and it is rooted in the fact that the normal function of this ligand is in the regulation of homeostasis. During disease progression, TGFβ signalling can go into override and, once unharnessed, results in more damage than good. The main goal in cancer therapy is therefore to downmodulate excessive levels of TGFβ ligands.
A major challenge in developing TGFβ inhibitors for cancer therapy has been the fact that these compounds are not cytotoxic or cytostatic to most tumour cells in vitro. They were developed to target properties of the tumour that are required for cancer progression, including
Box 3 | BMP-TGFβ-activin crosstalk in endothelial cells
Within the transforming growth factor-β (TGFβ) superfamily, the crosstalk between three subfamilies -activins/inhibins/Nodal, TGFβs and bone morphogenetic proteins (BMPs) -is well established during development and postnatal homeostasis of various organs 206, 207 . In vertebrates, the BMP-SMAD1/SMAD5/SMAD8 and activin-Nodal-TGFβ-SMAD2/SMAD3 signalling pathways execute antagonistic actions in different developmental contexts by inducing the expression of antagonistic factors, such as inhibitory SMADs (I-SMADs: SMAD6 and SMAD7). Some studies have shown that the common mediator SMAD (co-SMAD), SMAD4, is rate-limiting; therefore, when one of the two pathways is activated, it can negatively influence the other pathway by sequestering SMAD4. In endothelial cells, TGFβ can signal not only via canonical TGFβ receptor type I (TβRI)-SMAD2/SMAD3 but also via activin receptor-like kinase 1 (ALK1)-SMAD1/SMAD5/SMAD8 (REF. 36 ). In contrast to TGFβ-TβRI signallingmediated activation of SMAD2 or SMAD3, which leads to endothelium quiescence, TGFβ-ALK1 signalling induces SMAD1/SMAD5/SMAD8 activation and has been shown to stimulate endothelial cell migration, proliferation and tube formation, thus promoting angiogenesis 208 . BMP9 was shown to induce SMAD2/SMAD3 and SMAD1/ SMAD5/SMAD8 phosphorylation via signalling mediated by BMP receptor 2 (BMPR2), activin receptor type II (ACTRII) and ALK1 or ALK2. Cross-activation of TGFβ-specific and BMP-specific receptor-specific SMADs (R-SMADs) by a single ligand is believed to provide a mechanism for the ligand to fine-tune endothelial cell behaviour and function 36 . In summary, the crosstalk among signalling pathways mediated by different TGFβ family ligands exists in every tissue. However, the mechanism and the biological outcome of this crosstalk are highly species-, tissue-and context-dependent.
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Tumour-initiating cells (TICs). The putative cancer stem cells that have the ability to maintain tumour growth, differentiate into all cell types of a heterogenous tumour, and to re-establish secondary tumours with exceedingly high efficiency.
migration, invasion and metastasis, as well as effects on the tumour microenvironment (FIGS 3,4) . Standard cytotoxic screens used by the pharmaceutical industry to identify anticancer drugs were therefore not relevant, and therapeutic utility could only be determined by in vivo efficacy in animal models and ultimately in the clinic.
Two major concerns in TGFβ drug development have been the inadvertent inhibition of the tumour-suppressing arm of TGFβ signalling in cancer [120] [121] [122] and the development of adverse side effects unrelated to cancer, such as widespread inflammation, autoimmunity or cardiovascular defects that have been revealed by mouse gene knockout studies [19] [20] [21] 123 . Preclinical studies suggested that attenuation of TGFβ-mediated growth inhibition would not be a major issue 96, 124, 125 . However, clinical trials to date 82 have not revealed the cardiac valvulopathy 126 or hyperostosis and chondrocyte hypertrophy and hyperplasia 127 observed in rat preclinical toxicology studies. Moreover, there has been no widespread evidence of inflammatory complications in clinical trials reported to date 54, 82 . These reassuring safety findings are supported by evidence from patients with the rare disease multiple self-healing squamous epithelioma (MSSE), who have germline-null mutations in the gene encoding TβRI but develop only self-limiting and mostly non-malignant skin lesions 128 . Intriguingly, in a Phase I clinical trial of GC-1008 for the treatment of MetM, patients developed skin lesions, keratoacanthoma or squamous cell carcinoma (SCC) that were similar to the skin abnormalities reported in MSSE, with the appearance of keratoacanthoma and SCC seemingly influenced by the extent of exposure to GC-1008. These lesions, which appeared on sun-damaged skin, were manifested in approximately 25% of patients who received higher dose levels of GC-1008 and/or longer exposure to the drug, and the lesions resolved on drug withdrawal 91, 93 . To put this toxicity into context, non-melanoma skin cancers, such as SCC and keratoacanthoma, develop in approximately 15-30% of patients with MetM who are treated with BRAF inhibitors such as vemurafenib and dabrafenib 129 , and therapy with sorafenib and TNF antagonists produced similar findings 130, 131 . Recent data from studies with vemurafenib for MetM therapy suggest that these lesions arise from pre-existent mutant RAScontaining cells within sun-damaged skin 132 . Intriguingly, one study of keratoacanthoma that appeared in sorafenibtreated patients showed somatic TGFBR1 missense mutations 133 , one of which was also identified as a causative germline mutation for MSSE 128 . Cancer 'stem cells' , or tumour-initiating cells (TICs), are defined by their capacity to self-renew and to initiate and persistently propagate the entire tumour. Targeting the cancer stem cell for destruction or irreversible quiescence is therefore the Holy Grail of oncology, especially as these cells are exceedingly resistant to both chemotherapy and radiotherapy, and are responsible for tumour metastasis and recurrence after therapy 134 . Several groups have now reported the phenomenon that TGFβ-induced EMT can drive tumour cells towards a more 'stem cell-like' phenotype characterized by increased expression of stem cell markers and enhanced tumour-initiating activity in vitro and in vivo 43, 135 . In breast cancer 135 , the TGFβ and WNT signalling pathways were shown to be the most commonly activated signalling pathways in cancer stem cells that had been fractionated from the bulk tumour on the basis of expression of stem cell markers such as CD44 hi and CD24
low . In preclinical studies, TGFβ inhibitors have been shown to deplete the stem cell compartment in various cancers -including breast cancer 135 , glioblastoma [136] [137] [138] and chronic myeloid leukaemia 139 -which leads to increased lifespan in several mouse models of metastatic cancer. Anido et al. 137 showed that glioblastoma-initiating cells (GICs, which express the stem cell markers CD44, ID1, ID3, SOX2 and SOX4) responded to LY2109761 by downregulating the expression of 'stem cell' genes. Moreover, patient-derived glioblastoma neurospheres transplanted orthotopically into non-obese diabetic/severe combined immunodeficient mice (NOD/SCID mice, which do not have T cells or B cells) responded to LY2109761 by decreasing in size and reducing their expression of stem cell markers 137 . The same research team is currently undertaking a Phase I/II clinical trial for glioblastoma using the closely related drug LY2157299 (REF. 137 ). Importantly, they showed a reduction of CD44 and ID1 RNA levels after 2 months of LY2157299 treatment in tumour biopsy material from one patient with glioblastoma for whom a salvage surgical resection was performed both before and after 2 months on the trial 137 . The ability to reduce the number of stem cells in an aggressive tumour such as glioblastoma is a major coup.
It has been argued that TGFβ inhibitors might, however, release isolated and disseminated tumour (stem) cells from dormancy by initiating proliferation and/or disrupting the stem cell niche. A couple of recent studies may give credence to this notion, as systemic TGFβ inhibition resulted in increased numbers of circulating tumours as well as micro-and macro-metastases in mouse models of head and neck SCC and mammary cancer in vivo 140, 141 . It might therefore be wise to use TGFβ inhibitors in combination with cytotoxic drugs to coax tumour cells out of their quiescent niche while simultaneously targeting those that respond proliferatively to TGFβ inhibition using chemotherapy. This strategy may be highly beneficial for 'flushing out' dormant disseminated tumour , LY573636 is not a TGFβ-specific inhibitor. NSCLC, non-small-cell lung cancer; oligo, oligonucleotide; TβR, TGFβ receptor; TGFβ, transforming growth factor-β; TICs, tumour-initiating cells. A further cautionary note is warranted, however, on the basis of two reports indicating that TGFβ may decrease the cancer-initiating cell population of diffuse type gastric carcinoma 143 and breast carcinoma 144 despite having little or no effect on cellular proliferation. Finally, TGFβ inhibitors might act on the stem cell niche by recruiting bone marrow mesenchymal stem cell-derived myofibroblasts that home in on the primary tumour, contribute to the tumour microenvironment as cancer-associated fibroblasts and consequently promote tumour progression 145 .
Clearly there are tissue-and cell type-specific effects of TGFβ inhibition that can influence the action of TGFβ on the cancer stem cell and its niche 146 . Understanding the differential molecular mechanisms that elicit these variable responses will be critical to a judicious choice of treatment with TGFβ inhibitors or their derivatives. As TGFβ inhibitors are not directly cytotoxic, the use of these inhibitors in combination with cytotoxic chemotherapeutics may be particularly efficacious. The activation of TGFβ signalling in response to chemotherapeutics may drive the generation of cancer stem cells (via EMT), resulting in their chemoresistance 134 . This event may be targeted with TGFβ inhibitors, as demonstrated by the synergistic activity of doxorubicin and TGFβ inhibitor combination therapy on breast cancer growth and metastasis 147 . Studies in multiple myeloma also suggest that TGFβ inhibitors could potentiate the cytotoxic effects of melphalan and dexamethasone 148 . In vitro, the exposure of multiple myeloma cells to differentiated versus immature MC3T3-E1 pro-osteoblastic cells potentiated chemotherapy-induced multiple myeloma cell death. As TGFβ inhibition acts Transforming growth factor-β (TGFβ) signalling can be inhibited by: sequestering ligands using soluble receptor ectodomain constructs (ligand traps) derived from TGFβ receptor type II (TβRII) or TβRIII; using TGFβ-neutralizing antibodies; or with TβRII or TβRI kinase inhibitors. Furthermore, translation of TGFβ mRNA can be blocked by targeting TGFβ mRNA with antisense oligonucleotides, thus preventing the production of the ligand. Different small-molecule kinase inhibitors against TβRI have been developed to block its kinase activity. Peptide inhibitors against specific TGFβ ligands are also used. Other approaches block the transformation of TGFβ from the latent to the active form. Three molecules are shown that either affect TGFβ signalling indirectly (losartan) or that have an as-yet-unidentified target (tranilast and pirfenidone). All of these approaches decrease the initiation of intracellular receptor signalling pathways, such as phosphorylation of downstream receptor-specific SMADs (R-SMADs), and thereby blunt the transcriptional regulation of target genes. AT1, angiotensin II type 1 receptor; co-TFs, co-transcription factors; FOXH1B, forkhead box protein H1B; LEF, lymphoid enhancer-binding factor; LSKL, Leu-Ser-Lys-Leu peptide; TRX, thioredoxin.
within the bone microenvironment to elicit osteoblastic differentiation 148, 149 , this combinatorial approach holds great promise for the treatment of multiple myeloma and other bone metastatic cancers. Likewise, in a mouse model of serous gastric cell carcinoma, Ki26894 had an additive effect with a fluorouracil analogue in reducing tumour growth 150 . Finally, another mechanism whereby TGFβ inhibition can augment conventional therapies is in enhancing drug delivery to the tumour. There are reports that TGFβ inhibition can reduce interstitial tumour pressure 44 , which enhances the delivery of SMIs, and regulates vascular leakiness, which enhances the delivery of nanoparticle-encapsulated drugs, particularly in highly fibrotic and drug-refractile tumour types such as pancreatic cancer 151 . Adoptive T cell therapy involves the harvesting and ex vivo expansion of autologous tumour-specific CTLs followed by their reintroduction into the patient to stimulate tumour killing 152 . Used most extensively in the treatment of MetM and lung cancer, this therapy often fails owing to the apoptosis of re-grafted CTLs. Preclinical studies suggest that failure may be due to the direct effects of TGFβ on CTLs 153 , and strategies to prevent such failure include the use of genetically modified CTLs with reduced TGFβ responsiveness. Transduction of CTLs with a virus encoding a DNRII 154 has reached Phase I clinical trials, and recent preclinical data indicate that combining CTL therapy with TβRI-targeting SMIs may also significantly improve T cell survival and antitumour T cell cytotoxicity 155 . Augmenting adoptive T cell therapy with SMIs may be a particularly attractive application of TβRI SMIs as patients need not be exposed to genetically engineered T cells. Moreover, patients might only require short-term exposure to the drug for efficacy in this application, thus avoiding the side effects of long-term SMI drug exposure, such as inflammation 19 , cardiovascular complications 126 , bone and/or cartilage problems 127 , subphyseal hyperostosis as well as chondrocyte hypertrophy and/or hyperplasia, and reducing the risk of developing SMI drug resistance 156 . Another clinical application with great promise is augmenting radiotherapy by inhibiting the TGFβ pathway 10, 81, 157 . Radiation not only physically activates latent TGFβ in vitro but also induces the biological release of this growth factor as part of a stress response 158 . Several groups have reported the positive role of TGFβ in supporting the DNA damage repair pathway, particularly through activation of p53 and phosphorylation of ataxia telangiectasia mutated (ATM) after radiation therapy 159 .
Box 4 | Oncology trials to date
A two-part clinical trial of GC-1008 for the treatment of advanced metastatic melanoma (MetM) and renal cell carcinoma (22 patients) found the drug to be safe and well tolerated with no dose-limiting toxicities (DTLs). Five patients achieved at least stable disease as assessed by RECIST (response evaluation criteria in solid tumours) criteria, and therefore received extended treatment. One patient achieved a partial response with a greater than 75% reduction in the target lesion. The only adverse effect was keratoacanthoma-like lesions in sun-damaged skin of two of the patients with MetM. However, these resolved on cessation of drug treatment and were not malignant 93 . Despite these promising results, the pursuit of GC-1008 for oncology was terminated after Genzyme was acquired by Sanofi in late 2011.
Antisense Pharma has had success with trabedersen (AP12009) in glioblastoma, pancreatic cancer and colon cancer. Preclinical and clinical studies 70, 71, 73 indicate that neutralization of transforming growth factor-β2 (TGFβ2)-mediated immunosuppression, leading to activation of tumour-infiltrating natural killer cells, is the major mode of action. Intra-tumoural administration of trabedersen to glioblastoma led to shrinkage of the targeted tumour as well as tumours elsewhere in the brain. Three Phase I/II studies of trabedersen for recurrent or refractory high-grade glioma (glioblastoma) and anaplastic astrocytoma showed survival benefit compared with conventional chemotherapy 209 . A randomized, controlled Phase IIb study evaluating the efficacy and safety of two doses (10 and 80 mM) of trabedersen in comparison with standard therapy concluded that patients with glioblastoma on trabedersen had a threefold enhancement in cognitive function 2 and 3 years after therapy compared to standard chemotherapy 74 . However, questions have been raised about this most recent study 210, 211 . Wick and Weller 211 conceded that although trabedersen was clinically safe and that TGFβ inhibitors, in general, show promise for cancer therapy, the conclusions drawn by Bogdahn et al. 74 were premature. Because of other advances in both neurosurgical procedures and first-line standard of care for patients with glioblastoma 212 , the SAPPHIRE Phase III trial of trabedersen was recently halted owing to patient recruitment issues (ClinicalTrials.gov identifier: NCT00761280). Nevertheless, the drug has undergone a Phase I/II trial for patients with advanced pancreatic cancer, MetM or metastatic colorectal carcinoma, and showed excellent safety and encouraging survival results (ClinicalTrials.gov identifier: NCT00844064) 84 . Eli Lilly's clinical small-molecule inhibitor LY2157299 was found to be safe and well tolerated in a Phase I glioblastoma trial 82 . Of 28 patients treated in a dose escalation study (14 days on/14 days off treatment), at least three patients showed antitumour effects with durable responses beyond 1 year. As a result, the Eli Lilly anti-TGFβ signalling programme for oncology continues to be pursued with an ongoing Phase II trial of LY2157299, with or without gemcitabine, for hepatocellular carcinoma, glioblastoma and advanced pancreatic cancer, and with lomustine in patients with treatmentrefractory malignant glioma . Even short-term dosing with TβRI inhibitors might provide a considerable therapeutic advantage in potentiating radiotherapy, with the added benefit that the local activation of pro-tumorigenic stroma and tissue fibrosis -a major complication of radiation therapy 10 -may also be suppressed by these drugs. In partnership with Genzyme, this group is currently undertaking a Phase I trial of fresolimumab in combination with radiotherapy for metastatic breast cancer. Eli Lilly is also undertaking a Phase I/IIa trial to test the safety and efficacy of LY2157299 in combination with temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma 157 .
Myelodysplastic syndrome. Myelodysplastic syndrome (MDS) is characterized by abnormal myeloid and/or erythroid differentiation of bone marrow cells that results in various anaemias and cytopaenias. In one-third of MDS cases, a high-risk group of patients can progress to leukaemia. However, refractory cytopaenias are the major cause of morbidity and mortality in sufferers. It was recently shown that reduced expression of SMAD7, an inhibitor of TβRI, was a common and significant event observed in CD34 + myeloid progenitor cells in the bone marrow of patients with MDS 160 . Indeed, low levels of myeloid SMAD7 expression were seen in most patients with MDS, regardless of the risk for progression to leukaemia. Downregulation of SMAD7 expression sensitized myeloid precursors to TGFβ such that even very low levels of the ligand elicited an increase in TGFβ responsiveness, as defined by P-SMAD2 levels and enhanced immune-suppressive effect, thus providing another opportunity to utilize TGFβ inhibitors for therapeutic utility in human disease.
Treatment of primary CD34 + haematopoietic stem cells with LY2157299 suppressed the activation of TβRI by its ligand. Moreover, in a liver-specific TGFβ1-overexpressing transgenic mouse model of MDS that exhibits severe anaemia, LY2157299 decreased P-SMAD2 levels in the bone marrow and significantly increased the haematocrit of these mice. Importantly, in ten out of ten primary bone marrow cultures from patients with MDS, administration of LY2157299 significantly increased erythroid (burst-forming unit (BFU-E)) and myeloid (colony-forming unit (CFU); granulocytic monocytic) colony numbers in vitro, harbouring great promise for the treatment of patients with MDS 160 .
Fibrosis. IPF is a progressive, chronic and irreversible lung disease occurring in older adults, and has an unknown cause 161 . The main histological features of IPF are heterogeneous parenchyma, with areas of fibrosis and honeycombing alternating with areas of less-affected or normal parenchyma. IPF is characterized by a progressive reduction in lung function, with an estimated 20% survival prospect after 5 years, making it more lethal than many cancers. The progressive fibrotic reaction in IPF is associated with an epithelium-dependent fibroblast activation, in which TGFβ plays a major part 16 . TGFβ1, which is secreted by alveolar epithelial cells in patients with IPF, drives the process by promoting the migration, proliferation and differentiation of resident mesenchymal cells. αVβ6 integrin, which binds and activates latent TGFβ1 and TGFβ3, is highly induced following lung injury or fibrosis 162 . TGFβ activity 163 then promotes activation and differentiation of fibroblasts into myofibroblasts, which are specialized contractile cells that cause aberrant ECM deposition, leading to the destruction of lung architecture, scarring 162 and reduced lung function. TGFβ also promotes pulmonary EMT that additionally contributes to the expansion of fibroblasts and myofibroblasts 164 . Pirfenidone, a novel compound that inhibits TGFβ activity in vitro, decreased the rate of decline in vital lung capacity and marginally increased progressionfree survival in patients with IPF. Pooled data from two concurrent Phase III clinical trials in IPF indicated improvement in pulmonary function in the pirfenidonetreated group 165 . Currently, there are no US Food and Drug Administration (FDA)-approved drugs for IPF, and pirfenidone is the first such drug to be approved for IPF in Europe. Other approaches to develop TGFβ-based therapies for IPF include gene transfer of a soluble TβRII construct (as a ligand decoy), which attenuated injury and fibrosis in bleomycin-induced IPF in mice 166 . P144 (disitertide; Digna Biotech), a synthetic peptide that attenuates TGFβ activity and is derived from the extracellular domain of betaglycan, was also shown to reduce carbon tetrachloride-induced liver injury in mice 78 . P17, another Digna Biotech anti-TGFβ peptide, has been shown to be efficacious in attenuation of injury and fibrosis in bleomycin-induced IPF in mice 167 . Although P144 has been used clinically for skin fibrosis, drug delivery is an issue for the clinical development of P144 for IPF. However, Digna Biotech has recently partnered with Flamel Technologies to investigate the use of a proprietary drug delivery platform for this application (see the press release: 'Flamel Technologies and Digna Biotech Announce Multiple Product Development Agreement'). Other anti-TGFβ therapies in clinical trials for IPF include the pan TGFβ-neutralizing antibody GC-1008 (Genzyme) and the αVβ6 integrin-blocking antibody STX-100 (Stromedix) 168, 169 .
Renal fibrosis has long been thought to be driven by excess TGFβ, which results in renal scarring and, ultimately, kidney failure 170 . With the increasing incidence of diabetes and associated kidney damage in affluent countries, this is a clinical application of growing importance. Mice overexpressing an active form of TGFβ1 (from the liver) develop progressive liver and renal fibrosis 170 . Interestingly, although mice overexpressing active TGFβ1 develop progressive renal injury, latent TGFβ1 also has a protective role in renal fibrosis through negative effects on inflammation 49 . TGFβ1 mediates progressive renal fibrosis by stimulating the synthesis of ECM production while inhibiting its degradation 49 . TGFβ1 also mediates renal fibrosis by inducing the transformation of tubular epithelial cells into myofibroblasts through EMT in a similar way to the process seen in IPF 171 . Cardiac fibrosis is a pathological feature that is common to a number of forms of heart disease, including myocardial infarction, ischaemic, dilated and hypertrophic cardiomyopathies and congestive heart failure 36 . The cellular basis of cardiac fibrosis is the aberrant accumulation of collagens and other ECM proteins, which impair ventricular function and predispose to cardiac arrhythmias. Because TGFβ has pleiotropic effects in the cardiovascular system and as cardiac fibrosis is a multifactorial disease, the development of an effective therapy will require a detailed understanding of the role of the TGFβ signalling pathway in this pathogenesis. TGFβ, a potent stimulator of collagen production by cardiac fibroblasts, is induced in response to cardiovascular injury. The TGFβ-SMAD pathway activates the transcription of several key fibrotic genes, such as those encoding connective tissue growth factor (CTGF), fibronectin, collagens and plasminogen activator inhibitor 1 (PAI1) 36 . TGFβ reduces collagenase production and stimulates the expression of tissue inhibitor of metalloproteinases (TIMPs), resulting in an overall inhibition of ECM degradation and leading to excessive ECM accumulation. P144 has been investigated in a preclinical model of cardiac fibrosis 77 , and losartan can reverse fibrosis in a mouse model of hypertrophic cardiomyo pathy 174 ; however, no drug targeting the TGFβ pathway has yet reached clinical trials for this application. A recent study demonstrated that miR-21, which is regulated by SMADs upon TGFβ activation, is consistently induced by cardiac stress. As miR-21 plays a part in tumorigenesis by promoting cell proliferation, increased expression of miR-21 might contribute to the progression of fibrotic lesions 175 . ASOs against miR-21 might therefore become a novel therapeutic approach for treating cardiac fibrosis. Restenosis following coronary artery bypass and angioplasty. The development of fibromuscular intimal hyperplasia following angioplasty and coronary artery bypass surgery is a major clinical problem and can lead to coronary artery graft failure. The success of coronary artery reconstructive procedures is limited by the high incidence of restenosis secondary to intimal hyperplasia. TGFβ1 is a major player in the early development of intimal hyperplasia in arteries and peripheral vein grafts. The exact mechanism of action of TGFβ signalling in intimal hyperplasia and subsequent graft failure is unclear, but it is speculated that TGFβ1 contributes at multiple steps, including EMT, promotion of fibroblast, endothelial and vascular smooth muscle cell proliferation, increased collagen synthesis and deposition, and induction of fibrosis 177 . Soluble forms of the small, leucine-rich proteoglycans decorin and fibromodulin, which possess TGFβ-antagonist activity, exhibit potent intimal hyperplasia-suppressing effects in cultured human saphenous vein, offering the potential for therapeutic benefit after coronary artery bypass surgery [178] [179] [180] . The novel pyrrole-imidazole polyamide drug class, targeted to suppress TGFB1 gene transcription, showed efficacy in reducing neointimal hyperplasia and stimulating re-endothelialization of carotid arteries in a preclinical model of arterial injury 50 .
Scleroderma
Marfan syndrome. MFS is a connective tissue disorder that affects the musculoskeletal, ocular and cardiovascular systems. It is caused by mutations in the gene encoding an ECM protein, fibrillin 1 (FBN1) 181 . Growing evidence suggests that FBN1 mutations perturb not only the general integrity and elasticity of tissues but also -probably more crucially -local TGFβ signalling 11 . Normal fibrillin 1-containing microfibrils interact with the large latent TGFβ complex (LLC) to control the release of mature, active TGFβ 181 . Mutated fibrillin 1 fails to sequester latent TGFβ, leading to the promiscuous activation of TGFβ 11 . Thus, MFS highlights the critical role of microfibrils in regulating local concentrations of TGFβ and in maintaining the homeostasis, morphogenesis and function of various organs 181 . Dilation of the aortic root, which leads to aortic rupture and sudden death, is a major clinical issue for patients with MFS and patients of the Loeys-Dietz spectrum who carry mutations in TGFBR1, TGFBR2 and SMAD3. A mouse model of MFS carrying a heterozygous Fbn1 mutation developed an aortic aneurism similar to that of patients with MFS. Administration of TGFβ antagonists, including a TGFβ-neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker losartan, successfully rescued both cardiovascular and non-cardiovascular manifestations of MFS 12, 182 . As losartan is already in widespread clinical use for hypertension and has shown no adverse effects, this drug is currently being tested in Phase I/ II clinical trials for MFS (ClinicalTrials.gov identifiers: NCT00429364, NCT00593710, NCT00683124, NCT00723801, NCT00763893, NCT00782327 and NCT01145612) and may plausibly reduce this lifethreatening manifestation of MFS.
Postoperative scarring in ocular conditions. Trabeculectomy is a surgical procedure designed to reduce intraocular fluid pressure in patients with glaucoma. However, postoperative scarring and fibrotic blockage of the 'filtering bleb' that drains excess ocular fluid are serious complications of this procedure. In preclinical experiments, administration of neutralizing antibodies against human TGFβ2 (CAT-152) exhibited promising inhibition of scarring after glaucoma surgery in rabbits without having any adverse effects. Initial clinical trials with CAT-152 ameliorated scarring in patients who received trabeculectomy for intractable glaucoma 88, 183 ; however, Phase III clinical trials were unable to validate such beneficial effects 184 . Tranilast, another incidental TGFβ inhibitor, has also been used successfully to reduce re-occurrence of corneal fibrosis, or primary pterygium, following corneal surgery 185 . It is possible that topical application of more-specific TGFβ inhibitors might also be used in treating corneal haze and conjunctival scarring (TABLE 1) .
Challenges and considerations for TGFβ blockade
Individualized responses to TGFβ blockade. Many diseases being tackled with TGFβ inhibitors, including fibrosis, inflammation, autoimmunity and cancer, are complex in nature and show strong genetic predisposition owing to innate genetic variation between individuals. It is well established that there is considerable phenotypic diversity in the range of responses to reduced TGFβ signalling in vivo, which are dictated by differential inheritance of germline genetic variants. This is illustrated by the large spectrum of clinical severity and disease manifestations in individuals with mutations in TGFβ signalling pathway genes 8, 41, 186 . Moreover, in mouse models of cancer, asthma and vascular development, outcomes of reduced TGFβ1 levels are strongly influenced by interacting genetic modifier loci 5, 9, 186, 187 . It is therefore most rational, economical and safe to preselect patient populations before initiating anti-TGFβ drug treatment on the basis of surrogate markers of TGFβ involvement in the disease process (such as increased TGFβ ligand and P-SMAD levels, and specific disease characteristics) and contra-indications of possible adverse side effects (such as susceptibility to inflammation or certain vascular conditions). Peripheral blood may provide non-invasive markers that might be useful in this respect, including the ability to quantitatively screen patient responses to TGFβ inhibition on the basis of measuring P-SMAD2 levels in peripheral blood mononuclear cells (PMNCs) 188 . Similarly, potential adverse inflammatory effects could be predicted by examining specific immunological responses of PMNCs [189] [190] [191] [192] to TGFβ inhibition ex vivo.
Patient selection for TGFβ inhibitors in oncology.
The simplest biomarker for patient selection for TGFβ inhibitors in oncology is probably high circulating levels of TGFβ, as one major goal of this therapy is to reduce, but not totally ablate, TGFβ signalling 193 . As indicated above, non-invasive biomarkers for predicting patient responsiveness and efficacy of TGFβ inhibitors have been developed on the basis of measuring P-SMAD2 levels in PMNCs. Indeed, PMNCs can be treated with drugs ex vivo to determine, and thus predict, individual patient responses to SMIs 188, 193 . As TGFβ inhibitors certainly act to reduce tumour metastasis, the assay of circulating tumour cell number may also be a useful indicator for therapeutic response. Moreover, as many of the pro-tumorigenic effects of TGFβ are mediated by immune system modulation, it might be possible to monitor blood cell or plasma protein profiles for patient selection and for surrogate monitoring of patient responses.
In cancer (as well as non-malignant diseases), the outcome of reduced TGFβ signalling may be highly dependent on the innate genetic background of the individual, especially when considering tumour microenvironment effects, such as immune surveillance. Elucidating specifically which genetic variants influence signalling output will not only be useful for dissecting the intricacies of this signalling pathway in vivo, but may also provide predictive markers for the outcome (desired or undesired) of TGFβ signal inhibition. However, for cancer therapeutics, patient selection may be more complex, as the response of both the tumour cell and host (tumour microenvironment and normal patient tissue) to TGFβ blockade needs to be considered. Tumour biopsy and genetic analysis (for example, loss of TGFBR2, SMAD2 or SMAD4) 194, 195 might predict whether the tumour retains growth sensitivity to TGFβ. Molecular and histological analyses may also contribute to the prediction of tumour responses to TGFβ inhibition. The activation of alternative intracellular signalling pathways and transcription factor profiles has been associated with the switch from tumour suppression -by TGFβ -to tumour progression. These include an increased ratio of liver-enriched inhibitory protein (LIP) to liver-enriched activating protein (LAP), which are isoforms of CCAAT/ enhancer-binding protein-β (C/EBPβ), a central transcription factor that binds within the SMAD transcription factor complex to elicit TGFβ-mediated cytostatic responses 196 . Upregulation of SIX1 in breast cancer has also been shown to be pivotal in the growth-suppressive to tumour-progressive switch 197 , as has downregulation of DAB2 (REF. 198 ). Any of these tumour markers, possibly in combination, may be used in the future to predict tumour responses to TGFβ inhibition.
Finally, the effects of interactions with other anticancer drugs will need to be considered, as some drugs may resurrect the growth-inhibitory arm of the TGFβ signalling pathway, which would then counter-indicate their combinatorial use with TGFβ inhibitors 199 . Indeed, the ability to specifically target the pro-tumorigenic versus the tumoursuppressive effects of TGFβ on the tumour cell per se will require the development of next-generation drugs focusing on these downstream pathways. In the meantime, much research still remains to be undertaken to make inroads into the area of informed patient selection for oncology applications of TGFβ inhibitors.
Drug resistance. In oncology, the development of tumour drug resistance is inevitable 134, 200, 201 . It has been documented for standard chemotherapy, pathway-targeted therapies and is even common with anti-angiogenesis inhibitors 200, 201 . Acquired biochemical resistance of tumour cells to LY2109761 has been observed in a preclinical model of SCC and may have adverse consequences in driving a more stem cell-like phenotype 156 , although this remains to be tested. Carefully restricting TGFβ inhibitors to short-term or intermittent usage should avoid these complications 82 . Combinatorial and/ or sequential treatment with complementary drugs will also be important. It is clear that oncologists will need an arsenal of different anticancer drugs to tackle cancer, in much the same way that antibiotics have been developed to combat infectious diseases.
Conclusion and future directions
In conclusion, TGFβ signalling inhibitors are generally safe and may be efficacious in several clinical applications, especially in desperate cases such as end-stage cancer or IPF. The development of these drugs may offer further therapeutic opportunities. Counterintuitively, there have been reports suggesting that inhibition of the TGFβ signalling pathway may be beneficial in autoimmune disorders, such as multiple sclerosis, through downregulation of the T H 17 pathway 202, 203 . Recent studies have also suggested that TGFβ-SMAD3 signalling regulates glucose tolerance and energy homeostasis, and that blockade of the pathway may be used for regulation of diabetes and obesity 204 . The outlook for anti-TGFβ signalling therapy for numerous diseases appears bright. At least four companies are well on their way in clinical drug development, and further scientific and mechanistic studies are warranted in order to optimize patient selection and drugdosing regimens for each disease application.
